INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary NantKwest to Present at the 37th Annual Canaccord Genuity Growth Conference
CULVER CITY, Calif. --(BUSINESS WIRE)--Aug. 7, 2017-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell-based therapeutics company, today announced that the company will be presenting at the 37 th Annual Canaccord Genuity Growth Conference taking place August 9-10, 2017 in
View HTML
Toggle Summary NantKwest to Present at Jefferies 2018 Global Healthcare Conference
CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 5, 2018-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that Dr. Patrick Soon-Shiong , Chairman & CEO of NantKwest , will be presenting and conducting one-on-one meetings at the upcoming
View HTML
Toggle Summary NantKwest to Present at 2018 Cantor Global Healthcare Conference
CULVER CITY, Calif. --(BUSINESS WIRE)--Oct. 2, 2018-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at the upcoming Cantor Global Healthcare Conference on Tuesday, October 2 nd in New York City
View HTML
Toggle Summary NantKwest to Present at 2017 Bank of America Merrill Lynch Healthcare Conference
CULVER CITY, Calif. --(BUSINESS WIRE)--May 15, 2017-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that members of the company's management team will be presenting at the 2017 Bank of America Healthcare Conference on Thursday, May
View HTML
Toggle Summary NantKwest to Present and Provide Update at Upcoming Jefferies 2019 Annual Healthcare Conference
CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 3, 2019-- NantKwest ( Nasdaq:NK ), a leading clinical-stage, natural killer cell based therapeutics company, today announced that Dr. Patrick Soon-Shiong and Company management will be participating in the Jefferies 2019 Annual Healthcare Conference being
View HTML
Toggle Summary NantKwest to Participate at World Immunotherapy Congress
CULVER CITY, CA – March 1, 2019 - NantKwest (Nasdaq:NK), a member of the NantWorks ecosystem of companies,  a leading clinical-stage, natural killer cell based therapeutics company, today announced that the company will be making two presentations at the World Immunotherapy Congress in San Diego on
View HTML
Toggle Summary NantKwest to Participate at Upcoming Investment Conferences
NantKwest to Participate at Upcoming Investment Conferences CULVER CITY, CALIFORNIA-(BUSINESS WIRE), November 12, 2018 NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the company will be participating at a number of investment
View HTML
Toggle Summary NantKwest to Participate at the Cowen & Company 39th Annual Health Care Conference
CULVER CITY, CA.- March 10, 2019 –  NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the company will be participating and conducting one-on-one meetings at the Cowen 39th Annual Health Care Conference World Immunotherapy Congress
View HTML
Toggle Summary NantKwest to Host Investor Day on January 14, 2016
CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 22, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, announced today that
View HTML
Toggle Summary NantKwest to Host 4th Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs
CULVER CITY, Calif. --(BUSINESS WIRE)--Jan. 5, 2019-- NantKwest (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the human immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
View HTML